International Archives of Allergy and Immunology · 1998 · 11 citations · 6 references
Life SciencesImmunologyInfectious DiseasesHypersensitivityImmunotechnologyVaccine ImmunologyIge-mediated AllergyLiposomal FormulationsLiposome-based DeliveryToxoid VaccinesType I HypersensitivityType Iv HypersensitivityAntibodiesCombined Tetanus Toxoid VaccinesIntraperitoneal AdministrationLiposome Delivery SystemsLiposome ImmunogenicityLiposomesTetanus Toxoid VaccineVaccine Characterization
Tetanus toxoid (Ttd) was coupled to liposomes via glutaraldehyde. Intraperitoneal injection in BALB/c mice with Ttd-liposomes induced a substantial amount of anti-Ttd IgG antibody production and an extremely low level of anti-Ttd IgE antibody production. Mice immunized with Ttd-liposomes were successfully protected against a subsequent challenge with a lethal dose of tetanus toxin (Ttx). On the other hand, aluminum hydroxide-adsorbed Ttd (Ttd-alum) and plain Ttd solution induced the production of both IgG and IgE antibodies against Ttd. Moreover, secondary immunization with Ttd-liposomes in mice, in which anti-Ttd IgE antibody production was induced by Ttd-alum led to enhanced anti-Ttd IgG and a limited anti-Ttd IgE antibody production. When Ttd-liposome preparation was lyophilized, the efficacy of Ttd-liposomes was maintained for 6 months at 37 C, suggesting that this vaccine preparation would be stable without refrigeration. These results demonstrate the potential ability of Ttd-liposome conjugates to produce a tetanus vaccine which provides protection against (Ttx) while inducing the least amount of anti-Ttd IgE antibodies.
6
Adjuvants: current status, clinical perspectives and future prospects
L.D. Lise · Immunology Today · 1993 · 194 citations
The complicated task of monitoring vaccine safety.
S S Ellenberg, Robert T. Chen · PubMed · 1997 · 138 citations
Public Affairs, Preventive Medicine, Public Health Practice +14